About ADIENNE
ADIENNE is a Healthcare company based in Lugano (Switzerland) founded in 2004 by Antonio Francesco Di Naro. Mid-stage Biotech working on orphan diseases of various hematological and immunological diseases (GvHD, autoimmune, Hemolytic-Uremic Syndrome). ADIENNE offers products and services including TEPADINA and Monoclonal Antibody. Its focus areas include Life Sciences, Immunology, Drugs and GvHD. Its legal entity is ADIENNE S.r.l. Its competitors include Alexion and Alentis Therapeutics; 2 of its 2 listed competitors have raised funding.
Company details
Adienne was founded in 2004 and is headquartered in Lugano, Switzerland. Operations as a mid-stage biotechnology firm center on orphan diseases within hematology and immunology, such as GvHD, autoimmune conditions, and Hemolytic-Uremic Syndrome. The lead candidate, Begelomab, advances through Phase IIIII trials for steroid-resistant acute Graft-versus-Host Disease, with Orphan Drug Designation secured in the United States, European Union, and Switzerland.
- Headquarters Lugano, Switzerland
- Founders Antonio Francesco Di Naro
- SectorsHealthcare
- Website adienne.com
- Social LinkedIn
- Legal Name Adienne S.R.L.
Products & Services of ADIENNE
ADIENNE offers a comprehensive portfolio of products and services, including TEPADINA and Monoclonal Antibody.
Cytotoxic treatment for specific conditions via infusion bags.
Targets acute graft-versus-host diseases in patients.
People of ADIENNE
1 people are tracked at ADIENNE (1 in leadership).
| Name | Role | Group |
|---|---|---|
Antonio Francesco Di Naro | Founder | Leadership |
Complete people profiles for ADIENNE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of ADIENNE
ADIENNE has 2 listed competitors in our database, 2 of them funded. They include Alexion and Alentis Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| alentis.ch | 2019 | Basel, Switzerland | $365.66M | Therapies for fibrosis, cirrhosis, and liver cancer are developed. |
Detailed competitors of ADIENNE
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ADIENNE
Websites that share an audience with ADIENNE (adienne.com).
Websites whose visitors overlap most with ADIENNE. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| orphazyme.com | 92% | View details | |||
| cordenpharma.com | 87% | 26.2K | #789,402 | View details | |
| increlex.com | 62% | 1.9K | #5,508,119 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adienne
Complete news archive for ADIENNE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADIENNE
ADIENNE was founded in 2004.
ADIENNE is headquartered in Lugano, Switzerland. It is registered at Lugano, Ticino, Switzerland.
Adienne was founded in 2004 and is headquartered in Lugano, Switzerland. Operations as a mid-stage biotechnology firm center on orphan diseases within hematology and immunology, such as GvHD, autoimmune conditions, and Hemolytic-Uremic Syndrome. The lead candidate, Begelomab, advances through Phase IIIII trials for steroid-resistant acute Graft-versus-Host Disease, with Orphan Drug Designation secured in the United States, European Union, and Switzerland.
ADIENNE's top competitors include Alexion and Alentis Therapeutics.
ADIENNE offers TEPADINA and Monoclonal Antibody.
ADIENNE operates through Adienne S.R.L..